Company profile
Spencer Pharmaceutical Inc.
OTC: SPPH · Healthcare · Medical - Pharmaceuticals
PublicHQ Boston, Reports USD
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ —GM —SS 10
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, return on assets · ↓ revenue growth (YoY), workforce scale
Methodology →Revenue TTM
$670.2k
Rev growth YoY (TTM)
-69.5%
Net income (FY)
-$862.5k
Employees
2
as of 2026-08-29
Market cap
$29.4k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02003
Net income-$862.5k-$862.5k2003
Operating income$862.5k$862.5k2003
Total assets$4.2M$4.2M2003
Liabilities$379.6k$379.6k2003
Equity$3.9M$3.9M2003
Revenue trend
FY2001 – FY2003 · USD
FY01
FY02
FY03
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Spencer Pharmaceutical Inc.’s revenue?
Spencer Pharmaceutical Inc. booked $0 in FY2003 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
THC Therapeutics, Inc.——Health Advance Inc.——Transnational Cannabis Ltd.——Pazoo, Inc.——Scopus BioPharma Inc.——Healthcare Solutions Management Group, Inc.——Key facts
CEOMaximilien Arella
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersBoston, null
ExchangeOTC: SPPH
Employees2
IPO date2023-02-07
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.